Compare TRST & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | CGEM |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.5M | 873.4M |
| IPO Year | 1994 | 2020 |
| Metric | TRST | CGEM |
|---|---|---|
| Price | $46.17 | $14.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.11 |
| AVG Volume (30 Days) | 96.4K | ★ 732.3K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 26.46 | N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | $14.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.10 | $5.68 |
| 52 Week High | $48.45 | $16.74 |
| Indicator | TRST | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 56.96 |
| Support Level | $41.96 | $11.43 |
| Resistance Level | $46.89 | $15.66 |
| Average True Range (ATR) | 0.91 | 0.89 |
| MACD | 0.30 | 0.04 |
| Stochastic Oscillator | 77.47 | 75.25 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.